Clinical trials: Gefitinib, completed
Carcinoma, Non-Small-Cell Lung
MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
This a Phase I, Open-Label, Multicentre Study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of gefitinib in combination with MEDI4736 (anti PD-L1) in Subjects with Non-small cell lung…
- Trial name
- NCT02088112
- Testing
- Gefitinib, MEDI4736
- Where
- 7 sites in United States, Japan and 1 more
- Volunteers
- 56 people
- Sponsor
- MedImmune LLC
Lung Cancer
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00310154
- Testing
- docetaxel, gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Wake Forest University Health Sciences
Myelogenous Leukemia, Acute
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
The purpose of this study is to determine how effective, and to what extent, Iressa is in the treatment of acute myelogenous leukemia.
- Trial name
- NCT00130702
- Testing
- gefitinib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Non-small-cell Lung Cancer
Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1001. This is an open-label, single-arm, phase II interventional clinical trial.
- Trial name
- NCT01833572
- Testing
- Gefitinib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Fudan University
Lung Cancer
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with advanced lung cancer that…
- Trial name
- NCT00570401
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small-Cell Lung Carcinoma
Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response
The purpose of this study is to observe an improvement in overall response rate in NSCLC subjects who have been treated with gefitinib or erlotinib and are genotypically EGFR mutation positive or who have had a prior a response.
- Trial name
- NCT01167244
- Testing
- BMS-690514
- Where
- 4 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Bristol-Myers Squibb
Cancer
Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma
The investigators performed a randomized, double blind controlled, prospective study method on observation of Traditional Chinese Medicine (TCM) combined with targeted therapy maintenance to prolong the efficacy of long-term…
- Trial name
- NCT02889692
- Testing
- YiQiFang, YangYinFang, YiQiYangYinFang
- Volunteers
- 23 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Esophageal Cancer, Gastric Cancer
Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas
This study is for patients with esophageal, esophagogastric, or gastric cancer that has spread to other parts of the body. The purpose of this study is to test the safety and effectiveness of a new experimental drug called ZD…
- Trial name
- NCT00215995
- Testing
- Cisplatin, Irinotecan, ZD 1839
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Kidney Cancer
ZD 1839 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die.
- Trial name
- NCT00012337
- Testing
- gefitinib
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Carcinoma
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
The purpose of this study is to determine the safety, tolerability, and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with unresectable or metastatic non-small cell lung…
- Trial name
- NCT02039674
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Volunteers
- 267 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer, Cancer of the Fallopian Tube
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
Although initially responsive to cytoreductive surgery and platinum- and/or taxane-based chemotherapy, a majority of patients with epithelial ovarian cancer, cancer of the fallopian tube or the peritoneum will eventually relapse.
- Conditions
- Ovarian Cancer, Cancer of the Fallopian Tube, Peritoneal Cancer
- Trial name
- NCT00189358
- Testing
- ZD1839, tamoxifen
- Where
- Germany
- Sponsor
- AGO Study Group
Lung Cancer, Metastatic Cancer
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer
The aim of this study is to explore the efficacy and toxicity of icotinib combined with WBRT in treating patients with multiple brain metastases from NSCLC.
- Trial name
- NCT01514877
- Testing
- Icotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
EGFR-Mutant Lung Cancer
Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer
The purpose of this study is to test the safety of different ways of taking erlotinib. The investigators want to find out what effects, good and/or bad, combination daily low dose and twice weekly high dose erlotinib has on the…
- Trial name
- NCT01967095
- Testing
- erlotinib
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer (NSCLC)
Selumetinib in Combination With Gefitinib in NSCLC Patients
This is an open-label, non-randomized, multicenter phase Ib/II study, which is composed of a phase Ib dose escalation part and a phase II dose expansion part.
- Trial name
- NCT02025114
- Testing
- selumetinib
- Where
- 3 sites in Taiwan
- Volunteers
- 34 people
- Sponsor
- National Taiwan University Hospital
Carcinoma, Non-Small-Cell Lung
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib
The primary objective of this trial is to identify the Maximum Tolerated Dose of BIBW 2992 therapy when given continuously in combination with Sirolimus.
- Trial name
- NCT00993499
- Testing
- BIBW 2992, Sirolimus (rapamycin)
- Where
- 8 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer
Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Gefitinib and everolimus may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving gefitinib together with everolimus may kill more tumor cells.
- Trial name
- NCT00096486
- Testing
- everolimus, gefitinib
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
Iressa 2nd Line Phase III Study in Japan
In this study, among the patients with non-small cell lung cancer, those with metastasis or recurrence and previous treatment with chemotherapy will receive gefitinib or docetaxel, and we will compare the effectiveness and safety…
- Trial name
- NCT00252707
- Testing
- Gefitinib or Docetaxel
- Where
- 40 sites in Japan
- Volunteers
- 484 people
- Sponsor
- AstraZeneca
Squamous Cell Cancer, Cancer of Head and Neck
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
The purpose of this study is to compare the objectie tumour response rate between the cisplatin/5FU and cisplatin/5FU plus ZD1839 combination
- Trial name
- NCT00255476
- Testing
- gefitinib, cisplatin, 5-flourouracil
- Where
- United Kingdom
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Lung Cancer
Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Celecoxib may slow the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00068653
- Testing
- Celecoxib, ZD1839
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Head and Neck Cancer
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
Two different patient populations will be targeted for this study. The first population (SP1) will include patients with recurrent/metastatic head and neck cancers, excluding salivary gland carcinomas.
- Trial name
- NCT00228488
- Testing
- Gefitinib
- Where
- 2 sites in Hong Kong, Singapore
- Volunteers
- 60 people
- Sponsor
- AstraZeneca